Out-of-pocket costs and prescription reversals with oral linezolid

American Journal of Managed Care

Volumn 19, Issue 9, 2013, Pages 734-740

  Pasquale, Margaret K ^a   Louder, Anthony M ^a   Deminski, Michael C ^b   Chambers, Richard B ^b   Haider, Seema ^b  

^a Formerly of Comprehensive Health Insights Inc   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; ACETAMIDE DERIVATIVE; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ARTICLE; DRUG COST; HEALTH INSURANCE; HUMAN; LENGTH OF STAY; MEDICARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; OUT OF POCKET COST; PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; SKIN AND SOFT TISSUE INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; ADOLESCENT; ADULT; AGED; DRUG SUBSTITUTION; ECONOMICS; FACTUAL DATABASE; FINANCIAL MANAGEMENT; HEALTH MAINTENANCE ORGANIZATION; HOSPITAL READMISSION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDY; SOFT TISSUE INFECTIONS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; VERY ELDERLY; YOUNG ADULT;

ACETAMIDES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; DATABASES, FACTUAL; DRUG SUBSTITUTION; FINANCING, PERSONAL; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; LINEAR MODELS; MEDICARE PART D; MIDDLE AGED; OXAZOLIDINONES; PATIENT READMISSION; PNEUMONIA, BACTERIAL; RETROSPECTIVE STUDIES; SOFT TISSUE INFECTIONS; UNITED STATES; YOUNG ADULT;

EID: 84887233865     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Zyvox [full prescribing information]. New York: Pfizer Inc; 2008. http://labeling.pfizer.com/showlabeling.aspx?id=649. Accessed August 7, 2012.
2. Edelsberg J, Taneja C, Zervos M, et al. Trends in US hospital admissions for skin and soft tissue infections. Emerg Infect Dis. 2009; 15(9):1516-1518.
3. Gerber JS, Coffin SE, Smathers SA, Zaoutis TE. Trends in the incidence of methicillin-resistant Staphylococcus aureus infection in children's hospitals in the United States. Clin Infect Dis. 2009;49(1):65-71.
4. Klein E, Smith DL, Laxminarayan R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States,1999-2005. Emerg Infect Dis. 2007;13(12):1840-1846.
5. Landrum ML, Neumann C, Cook C, et al. Epidemiology of Staphylococcus aureus blood and skin and soft tissue infections in the US military health system, 2005-2010. JAMA. 2012;308(1):50-59.
6. Ray GT, Suaya JA, Baxter R. Trends and characteristics of cultureconfirmed Staphylococcus aureus infections in a large US integrated health care organization. J Clin Microbiol. 2012;50(6):1950-1957.
7. Desai M, Franklin BD, Holmes AH, et al. A new approach to treatment of resistant gram-positive infections: potential impact of targeted IV to oral switch on length of stay. BMC Infect Dis. 2006;6:94.
8. Ball AT, Xu Y, Sanchez RJ, Shelbaya A, Deminski MC, Nau DP. Nonadherence to oral linezolid after hospitalization: a retrospective claims analysis of the incidence and consequences of claim reversals. Clin Ther. 2010;32(13):2246-2255.
9. Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model. Med Care. 2002;41(1):84-89.
10. Sloan KL, Sales AE, Liu CF, et al. Construction and characteristics of the RxRisk-V: a VA-adapted pharmacy-based case-mix instrument. Med Care. 2003;41(6):761-774.
11. Sales AE, Liu CF, Sloan KL, et al. Predicting costs of care using a pharmacy-based measure risk adjustment in a veteran population. Med Care. 2003;41(6):753-760.
12. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol. 1992;45(2):197-203.
13. Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expenditures. Am J Manag Care. 2006;12(2):110-117.
14. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619.
15. Blough DK, Ramsey SD. Using generalized linear models to assess medical care costs. Health Serv Outcomes Res Methodol. 2000;1(2):185-202.
16. Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ. Costeffectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skinstructure infection using Bayesian methods for evidence synthesis. Value Health. 2011;14(5):631-639.
17. De Cock E, Krueger WA, Sorensen S, et al. Cost-effectiveness of linezolid versus vancomycin in suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia in Germany. Infection. 2009;37(2):123-132.
18. Bounthavong M, Hsu DI, Okamoto MP. Cost-effectiveness analysis of linezolid vs. vancomycin in treating methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections using a decision analytic model. Int J Clin Pract. 2009;63(3):376-386.
19. Schürmann D, Sorensen SV, De Cock E, Duttagupta S, Resch A. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft tissue infections in Germany. Eur J Health Econ. 2009;10(1):65-79.
20. Mullins CD, Kuznik A, Shaya FT, et al. Cost-effectiveness analysis of linezolid compared with vancomycin for the treatment of nosocomial pneumonia caused by methicillinresistant Staphylococcus aureus. Clin Ther. 2006;28(8):1184-1198.